118 related articles for article (PubMed ID: 1428236)
1. Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells.
Silvestrini R; Zaffaroni N; Villa R; Orlandi L; Costa A
Int J Cancer; 1992 Nov; 52(5):813-7. PubMed ID: 1428236
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of cisplatin cytotoxicity by lonidamine in primary cultures of human ovarian cancer.
Orlandi L; Zaffaroni N; Gornati D; Veneroni S; Silvestrini R
Anticancer Res; 1994; 14(3A):1161-4. PubMed ID: 8074467
[TBL] [Abstract][Full Text] [Related]
3. Modulation by lonidamine on the combined activity of cisplatin and epidoxorubicin in human breast cancer cells.
Silvestrini R; Gornati D; Zaffaroni N; Bearzatto A; De Marco C
Breast Cancer Res Treat; 1997 Jan; 42(2):103-12. PubMed ID: 9138599
[TBL] [Abstract][Full Text] [Related]
4. Lonidamine as a modulator of taxol activity in human ovarian cancer cells: effects on cell cycle and induction of apoptosis.
Orlandi L; Zaffaroni N; Bearzatto A; Villa R; De Marco C; Silvestrini R
Int J Cancer; 1998 Oct; 78(3):377-84. PubMed ID: 9766575
[TBL] [Abstract][Full Text] [Related]
5. Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum.
De Lena M; Lorusso V; Bottalico C; Brandi M; De Mitrio A; Catino A; Guida M; Latorre A; Leone B; Vallejo C; Gargano G
J Clin Oncol; 1997 Oct; 15(10):3208-13. PubMed ID: 9336357
[TBL] [Abstract][Full Text] [Related]
6. Modulation of melphalan and cisplatin cytotoxicity in human ovarian cancer cells resistant to alkylating drugs.
Gornati D; Zaffaroni N; Villa R; De Marco C; Silvestrini R
Anticancer Drugs; 1997 Jun; 8(5):509-16. PubMed ID: 9215615
[TBL] [Abstract][Full Text] [Related]
7. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
[TBL] [Abstract][Full Text] [Related]
8. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.
Rosbe KW; Brann TW; Holden SA; Teicher BA; Frei E
Cancer Chemother Pharmacol; 1989; 25(1):32-6. PubMed ID: 2590999
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of cisplatin cytotoxicity in human ovarian carcinoma cell lines by trifluoperazine, a calmodulin inhibitor.
Perez RP; Handel LM; Hamilton TC
Gynecol Oncol; 1992 Jul; 46(1):82-7. PubMed ID: 1634144
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of the apoptotic response as a basis for the therapeutic synergism of lonidamine and cisplatin in combination in human tumour xenografts.
De Cesare M; Pratesi G; Giusti A; Polizzi D; Zunino F
Br J Cancer; 1998; 77(3):434-9. PubMed ID: 9472640
[TBL] [Abstract][Full Text] [Related]
11. Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells.
Villa R; Orlandi L; Berruti A; Dogliotti L; Zaffaroni N
Int J Oncol; 1999 Jan; 14(1):133-8. PubMed ID: 9863019
[TBL] [Abstract][Full Text] [Related]
12. Correlation between HPLC-determined lonidamine serum levels and clinical response in patients with advanced ovarian cancer.
Bottalico C; Lorusso V; Brandi M; Micelli G; Rella CA; Coviello M; Atlante AM; Quaranta M; De Lena M
Anticancer Res; 1996; 16(6B):3865-9. PubMed ID: 9042272
[TBL] [Abstract][Full Text] [Related]
13. Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors.
Di Cosimo S; Ferretti G; Papaldo P; Carlini P; Fabi A; Cognetti F
Drugs Today (Barc); 2003 Mar; 39(3):157-74. PubMed ID: 12730701
[TBL] [Abstract][Full Text] [Related]
14. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R
Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of lonidamine combined with different DNA-damaging agents in the treatment of the MX-1 tumor xenograft.
Pratesi G; De Cesare M; Zunino F
Cancer Chemother Pharmacol; 1996; 38(2):123-8. PubMed ID: 8616901
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity of lonidamine alone and in combination with other drugs against murine RIF-1 and human HT1080 cells in vitro.
Ning SC; Hahn GM
Cancer Res; 1990 Dec; 50(24):7867-70. PubMed ID: 2253227
[TBL] [Abstract][Full Text] [Related]
17. In vitro effect of lonidamine on the cytotoxicity of mitomycin C and BCNU in human colon adenocarcinoma cells.
Villa R; Zaffaroni N; Orlandi L; Bearzatto A; Costa A; Silvestrini R
Eur J Cancer; 1994; 30A(10):1534-40. PubMed ID: 7833114
[TBL] [Abstract][Full Text] [Related]
18. Modulation of alkylating agents by lonidamine in vivo.
Teicher BA; Holden SA; Herman TS; Frei E
Semin Oncol; 1991 Apr; 18(2 Suppl 4):7-10. PubMed ID: 1903216
[TBL] [Abstract][Full Text] [Related]
19. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines.
Brown R; Clugston C; Burns P; Edlin A; Vasey P; Vojtĕsek B; Kaye SB
Int J Cancer; 1993 Oct; 55(4):678-84. PubMed ID: 8406999
[TBL] [Abstract][Full Text] [Related]
20. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
